News

Connect Biopharmaceuticals, Ltd., a clinical-stage company that discovers and develops novel immune modulators for the treatment of autoimmune diseases and cancer, today announces the completion of a $20

Dubbed ReLive, the phase 3 trial will evaluate the efficacy of intravenous (IV) administration of Livatag for treating the aggressive form of primary liver cancer. It will have patients

Guided by an experienced management team and preeminent board members and scientific advisors, Cue will use the proceeds to accelerate development of its novel platform of T cell

Under the initial terms of the partnership, ELC Group has commissioned PSR Group to develop 10 new products for human use, targeting therapeutic areas including oncology, pain management,

Intrexon intends to integrate and expand upon GenVec’s expertise in adenoviral vectors and cGMP drug product manufacturing to enhance its broad gene transfer capabilities that encompass multiple viral

The trial, Maestro, had enrolled 226 patients, with 135 of them in Functional Class II and was randomized in a 1:1 ratio. While one patient group was subjected to

This collaboration strengthens our combination strategy in immuno-oncology, and underscores Merck KGaA, Darmstadt, Germany's science-driven approach to discovering and developing novel compounds through both internal capabilities and external

The company plans to promptly initiate this trial, which is believed to be the first ever clinical evaluation of a genetically engineered, allogenic, off-the-shelf, natural killer cell for

The MAA was filed in December 2016. An opinion from the Committee for Medicinal Products for Human Use (CHMP) is expected in December of 2017, and decision is